Related Experiment Video
Updated: Aug 9, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
DNA adducts formed by a novel antitumor agent 11beta-dichloro in vitro and in vivo
Shawn M Hillier1, John C Marquis, Beatriz Zayas
1Department of Chemistry and Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Abstract:
The multifunctional molecule 11beta-dichloro consists of a ligand for the androgen receptor linked to a bifunctional alkylating group, permitting it to create DNA adducts that bind the androgen receptor. We propose that binding of the androgen receptor to 11beta-DNA adducts acts to both shield damaged sites from repair and disrupt the expression of genes essential for growth and survival. We investigated the formation 11beta-DNA adducts in tumor xenograft and nontumor tissues in mice. Using [14C]-11beta-dichloro, we show that the molecule remains intact in blood and is widely distributed in mouse tissues after i.p. injection. Covalent 11beta-guanine adducts identified in DNA that had been allowed to react with 11beta-dichloro in vitro were also found in DNA isolated from cells in culture treated with 11beta-dichloro as well as in DNA isolated from liver and tumor tissues of mice treated with the compound. We used accelerator mass spectrometry to determine the levels of [14C]-11beta-DNA adducts in LNCaP cells treated in culture as well as in liver tissue and LNCaP xenograft tumors in treated mice. The level of DNA adducts in tumor tissue was found to be similar to that found in LNCaP cells in culture treated with 2.5 micromol/L 11beta-dichloro. Our results indicate that 11beta-dichloro has sufficient stability to enter the circulation, penetrate tissues, and form DNA adducts that are capable of binding the androgen receptor in target tissues in vivo. These data suggest the involvement of our novel mechanisms in the antitumor effects of 11beta-dichloro.
Insights
The novel molecule 11beta-dichloro forms DNA adducts that bind the androgen receptor, potentially inhibiting tumor growth by blocking DNA repair and gene expression. This compound shows stability and tissue distribution in vivo.
Area of Science:
- Molecular Pharmacology
- Cancer Biology
- Drug Development
Background:
- The androgen receptor (AR) plays a crucial role in the growth and survival of various cancers, particularly prostate cancer.
- Targeting the AR is a key strategy in cancer therapy, but resistance mechanisms often emerge.
- Novel therapeutic agents are needed to overcome existing treatment limitations.
Purpose of the Study:
- To investigate the formation and function of DNA adducts created by the novel molecule 11beta-dichloro.
- To determine the in vivo distribution and stability of 11beta-dichloro.
- To explore the potential antitumor mechanisms of 11beta-dichloro through its interaction with the androgen receptor and DNA.
Main Methods:
- Synthesis and characterization of 11beta-dichloro, a molecule combining an AR ligand with a bifunctional alkylating agent.
- In vitro studies to assess DNA adduct formation and AR binding.
- In vivo studies using [14C]-labeled 11beta-dichloro in mouse models with tumor xenografts.
- Quantification of DNA adducts in various tissues using accelerator mass spectrometry (AMS).
Main Results:
- 11beta-dichloro is stable in circulation and widely distributed in mouse tissues after intraperitoneal injection.
- Covalent 11beta-guanine adducts were detected in DNA from cells in culture and from liver and tumor tissues of treated mice.
- The levels of DNA adducts in tumor tissue were comparable to those in cultured cells treated with 11beta-dichloro.
- The formed DNA adducts are capable of binding the androgen receptor in target tissues in vivo.
Conclusions:
- 11beta-dichloro demonstrates sufficient stability for systemic administration and tissue penetration.
- The formation of AR-binding DNA adducts in vivo suggests a novel mechanism for antitumor activity.
- These findings support the potential of 11beta-dichloro as a therapeutic agent targeting AR-dependent cancers through unique molecular interactions.
Related Concept Videos
Mutagenicity and Carcinogenicity
Inhibitors of Bacterial DNA Synthesis
Other Unique Bacteria

